Evidence map›Paper›PMID 40447713›Full record

ArticleScientific reports2025

Intelligent deep learning model for targeted cancer drug delivery.

Islam R Kamal, Saied M Abd El-Atty, S F El-Zoghdy, Randa F Soliman

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Circadian genesJournal of Zhejiang University. Science. B · 2025
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Islam R KamalDepartment of Computer Science, Faculty of Information Systems and Computer Science, October 6 University, Giza, 12585, Egypt.
Saied M Abd El-AttyDepartment of Electronics and Electrical Communications Engineering, Faculty of Electronic Engineering, Menoufia University, Menouf, 32952, Egypt.
S F El-ZoghdyDepartment of Mathematics and Computer Science, Faculty of Science, Menoufia University, Shebin El-Kom, 32511, Egypt.
Randa F SolimanMachine Intelligence Department, Faculty of Artificial Intelligence, Menoufia University, Shebin El-Kom, 32511, Egypt. randa_soliman@ai.menofia.edu.eg.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanotechnology and information communication technology (ICT) are being combined to develop innovative drug delivery systems for targeted sites, such as tumor cells. The particulate targeted drug delivery (PTDD) system involves drugs containing nanoparticles embedded in nanoscale devices (referred to as bio-nanomachines) that can cross vascular barriers, resulting in an increased concentration of the drug in the targeted cell or tumor. An artificial intelligence bio-cyber interface (AIBCI) operates in both forward and reverse directions, enabling the transfer or control of a desired drug dose without affecting healthy cells, facilitated by the Internet of Biological Nano Things (IoBNT). This paper proposes a multi-compartmental model with an AI bio-cyber interface based on molecular communication technology. The proposed model is formulated as a set of multi-differential equations designed to identify molecular communication-based bio-nanomachines, enabling the quantification of drug concentration at the targeted cell. Unlike conventional compartmental models, the present model is designed to connect both the exterior and interior of the human body. The results suggest that the model has the potential to improve the capacity of target cells to respond to therapeutic drugs while reducing adverse effects on healthy cells. The intra-body nanonetwork proposed in the present study proved superior performance in magnetifying the drug concentrations in diseased cells.

Indexed as

Antineoplastic AgentsDeep LearningDrug Delivery SystemsNeoplasmsHumansNanoparticlesAntineoplastic AgentsHealth care systemsInternet of bio-nano-thingsMolecular communicationNano-devicesNano-sensorsNanotechnology

Identifiers

PMID40447713
PMCPMC12125324

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.